ENTREVESTOR: After 15 months on TSX Venture, Appili’s market cap has grown to $65.9 million.

by Shana Cristoferi | Sep 15, 2020 | Appili Therapeutics, News

Read original article here   Appili Therapeutics Inc.’s common shares will begin trading on the main board of the Toronto Stock Exchange on Wednesday, after spending 15 months on the TSX Venture exchange. The Halifax-based company, which is working on bringing a...

NEWS RELEASE: Appili Submits Protocol for a Phase 3 Study Evaluating Favipiravir for the Treatment of Patients with COVID-19 Infections to the US FDA

by Shana Cristoferi | Sep 15, 2020 | Appili Therapeutics, News

Read original News Release  HALIFAX, Nova Scotia, September 11, 2020 – Appili Therapeutics Inc. (TSXV: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on anti-infective drug development, today announced that it has submitted a new...

Appili Therapeutics Announces Closing of Public Offering of $15,525,000 and Concurrent Private Placement of $1,440,000

by Shana Cristoferi | Jun 10, 2020 | Appili Therapeutics, News

Read more here Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”) announced the closing of its previously announced public offering (the “Public Offering”) of units (the “Units”). The Public Offering was made pursuant to an agency agreement entered into...

Health Canada Clears Appili Therapeutics’ Phase 2 Clinical Trial Evaluating Favipiravir as a Prophylactic Agent Against COVID-19 Outbreaks

by Shana Cristoferi | May 21, 2020 | Appili Therapeutics, News

Read original here Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, today announced that Health Canada provided regulatory clearance for Appili’s Phase 2 study evaluating FUJIFILM Toyama Chemical’s (FFTC) favipiravir as...

Appili Therapeutics Acquires Clinical Stage Antifungal Program From FUJIFILM Toyama Chemical

by Shana Cristoferi | Nov 21, 2019 | Appili Therapeutics, News

See original news release here Novel clinical-stage asset shows activity against drug-resistant fungal infections that pose a significant health threat and have limited treatment options November 21, 2019 04:00 AM Eastern Standard Time HALIFAX, Nova...

Appili Therapeutics Signs $3M USD Grant Contract with the United States Department of Defense to Develop Antibiotics that Target Superbugs

by Shana Cristoferi | Jul 2, 2019 | Appili Therapeutics, News

Appili’s multi-drug resistant antibiotic program has the potential to address public health threats for both military and civilian populations worldwide. HALIFAX, Nova Scotia, July 2, 2019 – Appili Therapeutics Inc. (TSXV: APLI) (the “Company” or “Appili”), a...